BTS guidelines for the management of chronic obstructive pulmonary disease

Thorax

Volumn 52, Issue SUPPL. 5, 1997, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748979747     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (172)

1. Medical Research Council. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet 1965;i:775-9.
2. Traver GA, Cline MG, Burrows B. Predictors of mortality in COPD. Am Rev Respir Dis 1979;119:895-902.
3. Thurlbeck WM. Chronic airflow obstruction in asthma. In: Bennington JL, ed. Major problems in pathology (Series No 5). Philadelphia: Saunders, 1976.
4. Nisar M, Walshaw MJ, Baris JE, Pearson MG, Calverley PMA. Assessment of airway reversibility of airway obstruction in patients with chronic obstructive airways disease. Thorax 1990;45:190-4.
5. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years observations on male British doctors. BMJ 1994;309:901-10.
6. Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis 1979;115:195205.
7. Oxman AD, Muir DCF, Shannon HS, Stock SR, Hnizdo E, Lange HJ. Occupational dust exposure and chronic obstructive pulmonary disease. A systematic overview of the evidence. Am Rev Respir Dis 1993;148:38-48.
8. Korn RJ, Dockery DW, Speizer FE, Ware JH, Ferris BG Jr. Occupational exposures and chronic respiratory symptoms. A population-based study. Am Rev Respir Dis 1987; 136:296-304.
9. Tashkin DP, Detels R, Simmons M, Liu H, Coulsen AH, Sayre J, et al. The UCLA population study of chronic obstructive respiratory disease: impact of air pollution and smoking on annual change in FEV,. Am jf Respir Crit Care Med 1994;149:1209-17.
10. Janus ED, Phillips NT, Carroll RW. Smoking, lung function and 2,-antitrypsin deficiency. Lancet 1985;i: 152-4.
11. Barker DJP, Godfrey KM, Fall C, Osmond C, Winter PD, Shaheen SO. Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive lung disease. BMJ 1991;303: 671-5.
12. Postma DS, de Vries K, Koeter GK, Sluiter HJ. Independent influence of reversibility of airflow obstruction and non-specific bronchial hyperreactivity in chronic airflow obstruction. Am Rev Respir Dis 1986;134:276-80.
13. O'Connor GT, Sparrow D, Weiss ST. The role of allergy and non-specific airway hyper-responsiveness in the pathogenesis of chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;140:225-52.
14. Fletcher CM Peto R, Tinker CM, Speizer FE. The natural history of chronic bronchitis and emphysema. Oxford: Oxford University Press, 1976.
15. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1:1645-8.
16. Tashkin DP, Clark VA, Coulson AH, Simmons M, Bourque LB, Reems C, et al. The UCLA population studies of chronic obstructive respiratory disease. VIII. Effects of smoking cessation on lung function: a prospective study of a free-living population. Am Rev Respir Dis 1984;130: 707-15.
17. Anthonisen NR. The Lung Health study: effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV,. JAMA 1994;272:1497-505.
18. Burrows B. Predictors of cause and prognosis of obstructive lung diseases. Eur Respir Rev 1991;l:340-5.
19. Anthonisen NR, Wright EC, Hodgkin JE. IPPB Trial Group. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:14-20.
20. Anthonisen NR. Prognosis in chronic obstructive pulmonary disease; results from multicenter clinical trials. Am Rev Respir Dis 1989;140:S95-9.
21. The Intermittent Positive Pressure Breathing Trial Group. Intermittent positive pressure breathing therapy of chronic obstructive pulmonary disease. Ann Intern Med 1983;99:612-20.
22. Burrows B. The course and prognosis of different types of chronic airflow limitation in a general population sample from Arizona: comparison with the Chicago COPD series. Am Rev Respir Dis 1989;140:S92-4.
23. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Hirth C, Roegel E. Long term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984;130:993-8.
24. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Erhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1989;36:752-8.
25. Cooper CB, Waterhouse J, Howard P. Twelve year clinical study of patients with hypoxic cor pulmonale given long term domiciliary oxygen therapy. Thorax 1987;42:105-10.
26. Office of Population Censuses and Surveys. Mortality statistics, cause: England and Wales 1992. Series DH2 no. 19. London: HMSO, 1993.
27. AndersonHR, EsmailA, HollowellJ, etal. Epidemiologically based needs assessment: lower respiratory disease. London: Department of Health, 1994.
28. Pearson MG, Littler J, Davies PDO. An analysis of medical workload by speciality and diagnosis in Mersey: evidence of a specialist to patient mismatch. J R Coll Phys 1994; 28:230-4.
29. Goldacre MJ, Ferguson JA. In-patient workload in medical specialities I. Demographic profiles and time trends from linked statistics. QJ Med 1995;88:649-60.
30. McCormick A, Fleming D, Charlton J. Morbidity statistics from general practice: Fourth national study 1991-2. London: Office of Population Censuses and Surveys, 1995.
31. Pearson MG, Calverley PMA. Clinical and laboratory assessment. In: Calverley PMA, Pride NB, eds. Chronic obstructive pulmonary disease. London: Chapman and Hall, 1994.
32. Wolkove N, Dajczman E, Colacone A, Kreisman H. The relationship between pulmonary function and dyspnoea in obstructive lung disease. Chest 1989;96:1247-51.
33. Connolly MJ, Crowley JJ, Charan NB, Neilson CP, Vestel RE. Reduced subjective awareness of bronchoconstriction by methacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. Thorax 1992; 47:410-3.
34. Kesten S, Chapman KR. Physician perceptions and management of COPD. Chest 1993;104:254-8.
35. France AJ, Prescott RJ, Biernacki W, Muir AL, MacNee W. Does right ventricular function predict survival in patients with chronic obstructive pulmonary disease? Thorax 1988;43:621-6.
36. Thurlbeck WM, Simon G. Radiographie appearance of the chest in emphysema. Am J Roentgenol 1978;130: 429-40.
37. Skillrid DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic pulmonary disease. A prospective matched case-controlled study. Ann Intern Med 1986;105: 503-7.
38. Anthonisen NR, Wright EC, IPPB Trial Group. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:814-9.
39. Nisar M, Baris JE, Pearson MG, Calverley PMA. Acute bronchodilator trials in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992;146:555-9.
40. Quanjer PH. Standardised Lung Function Testing. Official Statement of the European Respiratory Society. Eur Respir J 1993;6(Suppl 16):5-40.
41. Tweeddale PM, Alexander F, McHardy GJR. Short term variability in FEV, and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax 1987; 42:87-90.
42. Anthonisen NR, Wright EC, IPPB Trial Group. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:814-9.
43. Callahan CM, Cittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 1991; 114:216-23.
44. Rimmington LD, Spence DPS, Nisar M, Baris JE, Calverley PMA, Pearson MG. Predictors of 5 year mortality in COPD. Am Rev Respir Dis 1993;147:A323.
45. Weir DC, Gove RI, Robertson AS, Bürge PS. Corticosteroid trials in non-asthmatic airflow obstruction: comparison of oral prednisolone and inhaled beclomethasone dipropionate. Thorax 1990;4S:112-7.
46. Roberts CM, Bugler JR, Melchor R, Hetzel ML, Spiro SG. Value of pulse oximetry for long-term oxygen therapy requirement. Eur Respir J 1993;6:559-62.
47. Morgan MDL, Denison DM, Strickland B. Value of computed tomography for selecting patients with bullous emphysema. Thorax 1986;41:855-62.
48. Lehtonen J, Sutinen S, Ikaheimo M, Paakko P. Electrocardiographic criteria for the diagnosis of right ventricular hypertrophy verified at autopsy. Chest 1988;93: 839-42.
49. Cooper CB. Domiciliary oxygen therapy. In: Calverley P, Pride N. eds. Chronic obstructive pulmonary disease. London: Chapman and Hall, 1995: 495-526.
50. Royal College of Physicians. Health or smoking? Follow-up report. London: Pitman, 1983.
51. US Department of Health and Human Services. The health benefits of smoking cessation. A report of the Surgeon General. Washington: US Government Printing Office, 1989.
52. Flaxman J. Quitting smoking now or later: gradual, abrupt, immediate, and delayed quitting. Behav Ther 1978;9: 240-70.
53. Hajek P. Withdrawal-orientated therapy for smokers. Br J Addict 1989;84:591-8.
54. Lam W, Sze PC, Sacks HS, Chalmers TC. Meta-analysis of randomised controlled trials of nicotine chewing gum. Lancet 1987;ii:27-30.
55. Russell MÄH, Stapleton JA, Feyerabend C, Wiseman SM, Gustavsson G, Sawe U, et al. Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches. BMJ 1993;306:1308-12.
56. Jamrozik K, Vessey M, Fowler G, Wald N, Parker G, Van Vunakis H. Controlled trial of three different antismoking interventions in general practice. BMJ 1984;288:1499503.
57. Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD: estimates of its amount in comparison with that in normal subjects. Chest 1989;96:984-7.
58. Gross NJ, Skorodin MS. Anti-cholinergic, anti-muscarinic bronchodilators. Am Rev Respir Dis 1984;139:1185-91.
59. Guyatt GH, Townsend M, Nogradi S, Pugsley SO, Keller JL, Newhouse MT. Acute response to bronchodilator. An imperfect guide for bronchodilator therapy in chronic airflow limitation. Arch Intern Med 1988;148:1949-52.
60. Berger R, Smith D. Effect of inhaled metaproterenol on exercise performance in patients with stable 'fixed' airway obstruction. Am Rev Respir Dis 1988;138:626-9.
61. Corris PA, Neville E, Nariman S, Gibson GJ. Dose-response study of inhaled salbutamol powder in chronic airflow obstruction. Thorax 1983;39:292-6.
62. Van Schayck CP, Dompeling E, van Herwaarden CLA, Folgering H, Verbeek AL, van Der Hoogen HJ. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand. A randomised controlled study. BMJ 1991;303:1426-31.
63. Nisar M, Earis JE, Pearson MG, Calverley PMA. Acute bronchodilator trials in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992;146:555-9.
64. Ulrik CS. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled cross-over study. Thorax 1995;50:750-4.
65. Grove A, Lipworth BJ, Reid P, Smith RP, Ramage L, Ingram CG, et al. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996;51:689-93.
66. Braun SR, McKenzie WN, Copeland C, Knight L, Ellersieck M. A comparison of the effect of ipratropium and albuterol in the treatment of chronic airways disease. Arch Intern Med 1989;149:544-7.
67. Tashkin DP, Ashutosh K, Bleeker ER, Britt EJ, Cuzell DW, Cummiskey JM. Comparison of the anti-cholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease: a multicentre study. Am J Med 1986;81(Suppl 5a):61-5.
68. The Combivent inhalation aerosol study. Combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994;105:1411-9.
69. Leitch AG, Hopkin JM, Ellis DA, Merchant S, McHardy GJ. The effect of aerosol ipratropium bromide and salbutamol on exercise tolerance in chronic bronchitis. Thorax 1978;33:711-3.
70. Van der Palen J, Klein JJ, KerkhofT AHM, van Herwaarden CLA. Evaluation of the effectiveness of four different inhalers in patients with chronic obstructive pulmonary disease. Thorax 1995;SO:1183-7.
71. Newhouse M, Dolovich M. Aerosol therapy: nebuliser vs metered dose inhaler. Chest 1987;91:799-80.
72. Gross NJ, Petty TL, Friedman M, Skorodin MS, Silvers GW, Donoghue JF. Dose response to ipratropium as a nebulised solution in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;139:1188-91.
73. Morrison JFJ, Jones PC, Muers MF. Assessing physiological benefit from domiciliary nebulised bronchodilators in severe airflow limitation. Eur Respir J 1992;5:424-9.
74. Jenkins SC, Heaton RW, Fulton TJ, Moxham J. Comparison of domiciliary nebulised salbutamol and salbutamol from a metered dose inhaler in stable chronic airflow limitation. Chest 1987;91:804-7.
75. O'Driscoll BR, Kay EA, Taylor RJ, Weatherby H, Chetty MCP, Bernstein A. A long-term prospective assessment of home nebuliser treatment. Respir Med 1992;86:317-25.
76. British Thoracic Society. Current best practice for nebuliser treatment. Thorax 1997;52(Suppl 2):S1-106.
77. Murciano D, Auclair M-H, Pariente R, Aubier M. A randomised controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. A' EnglJMed 1989;320:1521-5.
78. McKay SE, Howie CA, Thomson AH, Whiting B, Addis GJ. Value of theophylline treatment in patients handicapped by chronic obstructive pulmonary disease. Thorax 1993;48:227-32.
79. Mulloy E, McNicholas WT. Theophylline improves gas exchange during rest, exercise and sleep in severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 148:1030-6.
80. Evans WW. Plasma theophylline concentrations, six minute walking distances and breathlessness in patients with chronic airflow obstruction. BMJ 1984;289:1649-51.
81. Cooper CB, Davidson AC, Cameron IR. Aminophylline, respiratory muscle strength and exercise tolerance in chronic obstructive airway disease. Clin Respir Physio! 1987;23:15-22.
82. Murciano D, Aubier M, Lecolguic Y, Pariente R. The effects of theophylline on diaphragmatic strength and exercise tolerance in patients with chronic obstructive pulmonary disease. A' Engl J Med 1984;322:349-53.
83. Peake MD, Chrystyn J, Mulley BA. Response to oral theophylline in severe chronic obstructive airways disease. BMJ 1989;298:523-4.
84. Tsui SJ, Self TH, Burns R. Theophylline toxicity: update. Ami Allergy 1990;64:241-57.
85. Van Schayck CP, Folgering H, Harbers H, Maas KL, van Weel C. Effects of allergy and age on responses to salbutamol and ipratropium in moderate asthma and chronic bronchitis. Thorax 1991;46:355-9.
86. Saetta M, Di Stephane A, Maestrelli P, Ferraresso A, Drigo R, Potena A, et al. Activated T lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993;147:301-6.
87. Nagai A, Thurlbeck W M, Konno K. Responsiveness and variability of airflow obstruction in chronic obstructive pulmonary disease: clinicopathologic correlative studies. Am J Respir Crit Care Med 1995;151:635-9.
88. Nagai A, West WW, Thurlbeck WM. The National Institutes of Health. Intermittent positive pressure breathing trial: pathology' studies II. Correlation between mor-phologic findings, clinical findings and evidence of airflow obstruction. Am Rev Respir Dis 1985;132:946-53.
89. Postma DS, Steenhuis EJ, Weele Van der LTh, Sluiter HJ. Severe chronic airflow obstruction: can corticosteroids slow down progression? Eur J Respir Dis 1985;67:56-64.
90. Postma DS, Peters I, Steenhuis EJ, Sluiter HJ. Moderately severe chronic airflow obstruction. Can corticosteroids slow down progression? Eur Respir J 1988;l:22-6.
91. Dompeling E, van Schayck CP, Molema J, Folgering H, van Grunsven PM, van Weel C. Inhaled beclomethasone improves the course of asthma and COPD. Eur Rcspir J 1992;5:945-52.
92. British Thoracic Society, National Asthma Campaign, Royal College of Physicians of London, a al. The British guidelines on asthma management. Thorax 1997; 52(Suppl 1):S1-21.
93. Petty TL. The national mucolytic study. Results of a randomised double blind placebo controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990;97:75-83.
94. Bowman R, Backer U, Larsson S, Melander B, Wahlandel L. Oral N-acetylcysteine reduces exacerbation rate in chronic bronchitis. Em Respir J 1983;64:405-15.
95. British Thoracic Society Research Committee. Oral Nacetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax 1985;40:832-5.
96. Voisin C, Howard P, Ansquer JC. Almitrine and bismesylate: a long-term placebo controlled double blind study in chronic obstructive pulmonary disease. Bull Eur Physiopaihol Respir 1987:239(Suppl ll):167-82.
97. Howard P, Empey D, Harrison B, et al. Lower dose almitrine bismesylate in hypoxaemic chronic bronchitis. Eur Respir J 1989:2(Suppl 8);774S.
98. MacNee W. State of the Art: Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Am J Respir Grit Care Med 1994;150:part 1 833-52; part II 1158-68.
99. American Thoracic Society. Evaluation of impairmentdisability secondary to respiratory disorders. Am Rev Respir Dis 1986;133:1205-9.
100. Hunter ABN, Carey MA, Larsh HW. The nutritional status of patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1981;124:376-81;
101. Hunter ABN, Carey MA, Larsh HW. The nutritional status of patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985;132:1347-65.
102. Fitting JW. Nutritional support in chronic obstructive lung disease. Thorax 1992;47:141-3.
103. Caiman KC. Influenza immunisation. Letter from the Chief Medical Officer, 8th October 1993. Department of Health PL/CMO(93): 13.
104. Kilbourne ED. Inactivated influenza vaccines. In: Plotkin SA, Mortimer EA, eds. Vaccines. Philadelphia: WB Saunders, 1988: 420-34.
105. American College of Physicians Task Force on Adult Immunization. Infectious Diseases Society of America. Guide for adult immunisation. 2nd ed. Philadelphia: American College of Physicians, 1990.
106. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. A7 Engl J Med 1991;325:1453-60.
107. Jones PW, Baveystock CM, Little-Johns P. Relationship between general health measured with the sickness impact profile and respiratory symptoms, physiological measures and mood in patients with chronic airflow limitation. Am Rev Respir Dis 1989;140:1538-43.
108. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure for chronic airflow limitation: the St George's respiratory questionnaire. Am Rev Respir Dis 1992;145:1321-7.
109. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring the quality of life in asthma. Am Rev Respir Dis 1993; 147:832-8.
110. Guyatt G. Measuring health status in chronic airflow limitation. Eur Respir J 1988;l:560-4.
111. Mahler PDA, Rosialto RA, Harmer A, Lantine T, McGovern JF, DaubenspekJA. Comparison of clinical dyspnoea ratings and psychophysical measurements of respiratory' sensation in obstructive airways disease. Am Rev Respir Dis 1987;135:1229-33.
112. Hay JG, Stone P, Carter J, Church S, Eyre-Brook A, Pearson MG, et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive airways disease. Eur Respir J 1993;5:659-64.
113. Woodcock AA, Gross ER, Geliert A, Shah S, Johnson M, Geddes DM. Effects of dihydrocodeine, alcohol and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med 1981;305:1611-6.
114. Johnson MA, Woodcock AA, Geddes DM. Dihydrocodeine for breathlessness in 'pink puffers'. BMJ 1983;276:675-7.
115. Mitchell-Heggs P, Murphy K, Minty K, Guz A, Patterson SC, Minty PS, el al. Diazepam in the treatment of dyspnoea in the pink puffer syndrome. Q J Med 1980; 193:9-20.
116. American Thoracic Society. Guidelines for pulmonary rehabilitation. Am Rev Respir Dis 1981;124:663-6.
117. Folgering H, DeKhuijzen R, Cox N, Van Herwaarden C. The rationale of pulmonary rehabilitation. Eur Respir Rev 1991;6:464-71.
118. Goldstein RS, Gort EH, Stubbing D, Arendano MA, Guyatt GH. Randomised controlled trial of respiratory rehabilitation. Lancet 1994;344:1 394-7.
119. Wijkstra PJ, Van Altena R, Kraan J, Often V, Postma DS, Koeter GH. Quality of life in patients with chronic obstructive pulmonary disease improves after rehabilitation at home. Eur Respir J 1994;7:269-73
120. Laçasse Y, Wong E, Guyatt GH, King D, Cook DJ, Goldstein RS. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet 1996; 348:1115-9.
121. Niderinan MS, Clements PH, Fein AM, Feinsilver SH, Robinson DA, Ilowite JS, eî al. Benefits of a multidisciplinary pulmonary rehabilitation programme. Chest 1991;99:798-804.
122. Morgan AD, Peck DF, Cannon DR, McHardy GJR. Psychological factors contributing to disproportionate disability in chronic bronchitis. J Psychosomatic Res 1983; 27:259-61.
123. Clark CJ. Strategies for the evaluation of rehabilitation treatment. Eur Respir Rev 1991;6:475-81.
124. Smith K, Hook D, Guyatt GH, Madhavan J, Oxman AD. Respiratory muscle training in chronic airflow limitation: meta-analysis. Am Rev Respir Dis 1992;145:533-9.
125. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxaemic chronic obstructive lung disease. A clinical trial. Ann Intern Med 1980;93:391-8.
126. Medical Research Council Working Group. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis emphysema. Lancet 1981;i:681-6.
127. Department of Health. Domiciliary oxygen therapy service. Drug tariff Pan X. London: HMSO, 1990.
128. Bloom BS, Daniel JM, Wiseman M, Knorr RS, Cebul R, Kissick WL. Transtracheal oxygen delivery and patients with chronic obstructive pulmonary disease. Respir Med 1989;83:281-8.
129. Walshaw MJ, Lim R, Evans CC. Prescription of oxygen concentrators for long term oxygen treatment: reassessment in one district. BMJ 1988;297:1030-2.
130. Morrison D, Skwarski K, MacNee W. A review of the prescription of domiciliary long-term oxygen in Scotland. Thorax 1995;50:1103-5.
131. Restrick LJ, Paul EA, Braid GM, Cullinan P, MooreGillon J, Wedzicha JA. Assessment and follow-up of patients prescribed long term oxygen therapy. Thorax 1993;48:708-13.
132. Lock SH, Paul EA, Rudd RM, Wedzicha JA. Portable oxygen therapy: assessment and usage. Respir Med 1991 ; 85:407-12.
133. Corris P. Lung transplantation. In: Calverley PMA, Pride NB, eds. Chronic obstructive pulmonary disease. London: Chapman and Hall, 1995: 562-70.
134. Scott JP, Higenbottam TW, Sharpies L, Clelland CA, Smyth RL, Stewart S, et al. Risk factors for obliterative bronchiolitis in heart-lung transplant recipients. Transplantation 1991;51:813-7.
135. Pearson MG, Ogilvie CMO. Surgical treatment of emphysematous bullae: late outcome. Thorax 1983;38:1347.
136. Davies L, Calverley PMA. Lung volume reduction surgery in chronic obstructive pulmonary disease. Thorax 1996; 51(Suppl 2):529-34.
137. Light RW, Merrill EJ, Despars JA, et al. Prevalence of depression and anxiety in patients with COPD: relationship to functional capacity. Chest 1985;87:35-8.
138. Schwanz JS, Bencowitz HZ, Moser KM. Air travel hypoxaemia with chronic obstructive pulmonary disease. Ann Intern Med 1984;10:473-7.
139. Dennison DJ. Adverse environments. In: Brewis RAL, Gibson GJ, Geddes DM, eds. Respiratory medicine. London: Balliere Tyndall, 1990: 1503-4.
140. Royal College of Physicians. Disabling Chest Disease: Prevention and Care. JR Coll Phys Land 1981;15:69-87.
141. Cockroft A, Bagnall P, Heslop A, Andersson N, Heaton R, Batstone J, et al. Control trial of respiratory health worker visiting patients with chronic respiratory disability. BMJ 1987;294:225-8.
142. Georgopoulos D, Anthonisen NR. Symptoms and signs of COPD. In Cherniak NS, ed. Chronic obstructive pulmonary disease. Philadelphia: Saunders, 1991: 357-63.
143. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
144. Calverley PMA. Symptomatic bronchodilator treatment. In: Calverley PMA, Pride NB, eds. Chronic obstructive pulmonary disease. London: Chapman and Hall, 1994.
145. Calverley PMA, Howatson R, Flenley DC, Lamb D. Clinico-pathological correlations in cor pulmonale. Thorax 1992;47:494-8.
146. Jeffrey AA, Warren PM, Flenley DC. Acute hypercapnic respiratory failure in patients with chronic obstructive lung disease; risk factors and use of guidelines for management. Thorax 1992;47:34-40.
147. Dünn WF, Nelson SB, Hubmayr RD. Oxygen induced hypercarbia in obstructive pulmonary disease. Am Rev Respir Dis 1991;144:526-30.
148. Bazuaye EA, Stone TN, Corns PA, Gibson GJ. Variability in inspired oxygen concentrations with nasal cannulae. Thorax 1992;47:609-11.
149. Costello RW, Liston R, McNicholas WT. Compliance at night with low flow oxygen therapy: a comparison of nasal cannulae and venturi face masks Thorax 1995;50:405-6.
150. Shrestha M, O'Brian T, Maddox R, Gourley HR, Ried G. Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbations with the addition of ipratropium bromide to agonist therapy. Ann Emerg Med 1991;20:1206-9.
151. O'Driscoll BR, Taylor RJ, Mosley MG, Chambers DJ, Beinstein A. Nebulized Salbutamol with or without ipratropium bromide in acute airflow obstruction. Lancet 1989;i: 1418-20.
152. Fernandez A, Munoz J, De la Calle B, Alia A, Izpeleta A, De laCalle MA, et al. Comparison of one versus two bronchodilatory drugs in ventilated COPD patients. Intensive Care Med 1994;20:199-202.
153. Moayyedi P, Congleton J, Page RL, Pearson SB, Muers MH. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 1995; 50:834-7.
154. Rice KL, Leatherman JW, Duane PG, Snyder LS, Harmon KR, Abel J, et al. Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial. Ann Intern Med 1987;107:305-9.
155. Blasi F, Legnani D, Lombarde VM, Negretto GG, Magiliano E, Pozzoli R, et al. Chlainydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993;6: 19-22.
156. Guidelines for the management of community acquired pneumonia in adults admitted to hospital. Br j Hasp Med 1993;49:346-50.
157. Albert RK, Martin TR, Lewis SW. Controlled clinical trials of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 1980; 92:753-8.
158. Thromboembolic Risk Factors Consensus Group. Risk and prophylaxis for venous thrombo embolism in hospital patients. BMJ 1992;305:567-73.
159. Sutton PP. Chest physiotherapy; time for reappraisal. Br J Dis Chest 1988;82:127-37.
160. Bott J, Carroll MP, Conway J, Keilty SE, Ward EM, Brown AM, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet 1993;341:1555-67.
161. Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A, et al. Non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. NEnglJ Med 1995;338:817-22.
162. Meecham-Jones DJ, Paul EA, Graham-Clark C, Wedzicha JA. Nasal ventilation in acute exacerbations of chronic obstructive pulmonary disease: effect on arterial blood gas tensions. Thorax 1994;49:1222-4.
163. Vitacca M, Rubini F, Foglio K, Scalvini S, Nava S, Ambrosino N. Non-invasive modalities of positive pressure ventilation improve the outcome of acute exacerbations in COLD patients. Intensive Care Med 1993;19:450-5.
164. Costello R, McNicholas WT. Five year follow-up of respiratory failure in COPD. Thorax 1993;48:419P.
165. Kelly CA, Gibson GJ. Relation between FEV, and peak expiratory flow in patients with chronic obstructive pulmonary disease. Thorax 1988;43:335-6.
166. American Thoracic Society. Standardisation of spirometry, 1994 update. Am J Respir Cril Care Med 1995;152:110736.
167. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson GJ,Howard P, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1398-420.
168. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;1S2:S77-121.
169. Lamb D. Pathology. In: Calverley PMA, Pride NB. Chronic obstructive pulmonary disease. London:Chapman and Hall, 1995.
170. Snider GL, Klenerman J, Thurlbeck WM, Bengali ZH. The definition of emphysema: Report of a National Heart and Blood Institute, Division of Lung Disease, Workshop. Am Rev Respir Dis 1985;132:182-5.
171. Kirn WD, Eidelman DH, Izquierdo JL, Ghezzo H, Saetta MP, Cosio MG. Centrilobular and panlobular emphysema in smokers; two distinct morphologic and functional entities. Am Rev Respir Dis 1981;141:1385-90.
172. Ollerenshaw SL, Woolcock AJ. Characteristics of the inflammation in biopsies from large airways of subjects with asthma and subjects with chronic airflow limitation. Am Rev Respir Dis 1992;145:922-7.